000403 派林生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)7.1138.5638.90110.72721.070
总资产报酬率 ROA (%)6.1387.3697.7928.92112.719
投入资产回报率 ROIC (%)6.5927.9998.4899.91813.801

边际利润分析
销售毛利率 (%)50.51651.48152.12746.07248.820
营业利润率 (%)33.79229.85327.58323.35120.982
息税前利润/营业总收入 (%)30.82127.07725.15720.90720.788
净利润/营业总收入 (%)28.71326.25824.43419.85817.399

收益指标分析
经营活动净收益/利润总额(%)98.560100.16398.707105.73999.987
价值变动净收益/利润总额(%)3.034-1.6811.20617.0100.000
营业外收支净额/利润总额(%)-3.100-1.029-0.460-0.528-1.429

偿债能力分析
流动比率 (X)4.0653.7153.1763.8451.352
速动比率 (X)2.7582.7292.5262.6940.668
资产负债率 (%)13.56914.00414.04610.72442.437
带息债务/全部投入资本 (%)6.4995.9874.5111.270--
股东权益/带息债务 (%)1,423.0401,551.4232,083.6397,632.613278.228
股东权益/负债合计 (%)637.559614.644612.517832.250135.422
利息保障倍数 (X)-15.769-10.952-10.939-9.005204.113

营运能力分析
应收账款周转天数 (天)82.471109.718102.62274.2070.000
存货周转天数 (天)295.661244.231213.018199.8770.000